Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study-Reference-Cited by-同舟云学术

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

Published:2009-01 Issue:1 Volume:63 Page:46-55
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:

Author:

Nauck M. A.,Ellis G. C.,Fleck P. R.,Wilson C. A.,Mekki Q.,

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2008.01933.x/fullpdf

Reference32 articles.

1. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV;Feng;J Med Chem,2007

2. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

3. Enhancing incretin action for the treatment of type 2 diabetes;Drucker;Diabetes Care,2003

4. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins;Gallwitz;Rev Diabet Stud,2005

5. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans;Holst;Am J Physiol Endocrinol Metab,2004

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial;Diabetes, Obesity and Metabolism;2024-04-11

2. Dermatological side effects of dipeptidyl Peptidase-4 inhibitors in diabetes management: a comprehensive review;Clinical Diabetes and Endocrinology;2024-03-25

3. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature;Frontiers in Molecular Biosciences;2023-05-23

4. Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized, double‐blind, placebo‐controlled, superiority, phase III clinical trial;Diabetes, Obesity and Metabolism;2022-07-22

5. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials;BMJ;2022-06-28